4 news items
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
ZNTL
29 May 24
the potential for azenosertib to be first-in-class and best-in-class; the potential for azenosertib to benefit patients across various tumor
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
ZNTL
23 May 24
product candidates, including azenosertib; and the potential benefits of azenosertib, including the potential benefits of the design thereof
Zentalis Pharmaceuticals To Highlight Preclinical Data Demonstrating That WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-Tumor Activity With KRAS(G12C) Inhibitors At AACR Annual Meeting 2024
ZNTL
2 Apr 24
to provide clinical benefit as a combination therapy.Poster Presentation DetailsTitle
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
ZNTL
2 Apr 24
for azenosertib to provide clinical benefit as a combination therapy.Poster Presentation Details
- Prev
- 1
- Next